ICU Medical Q4 Expected to Fall 14.6% to $530.9M, EPS $1.69
ICU Medical posted $533.3 million in Q3 revenue, beating analysts by 4.8% despite an 8.1% YoY decline, and topped EPS guidance. For Q4, analysts forecast a 14.6% revenue drop to $530.9 million and adjusted EPS of $1.69.
1. Q3 Performance
ICU Medical reported Q3 revenue of $533.3 million, surpassing analyst forecasts by 4.8% despite an 8.1% year-on-year decrease, and delivered an EPS beat that exceeded both quarterly and full-year guidance estimates.
2. Q4 Forecast
Analysts predict Q4 revenue will decline 14.6% year-on-year to $530.9 million, compared with a prior 8% gain in the same quarter last year, and project adjusted earnings of $1.69 per share.
3. Peer Comparisons
Within the healthcare equipment segment, Artivion achieved 19.2% revenue growth but missed estimates by 0.8%, while Envista’s 15% revenue gain topped expectations by 10.6%, prompting a 10% drop in Artivion’s stock and a 17.8% jump in Envista’s.
4. Analyst Sentiment and Price Target
Analyst coverage has remained stable over 30 days, reflecting confidence in ICU’s performance; the stock has fallen 3.2% over the last month against a 3.5% sector decline and carries an average price target of $180.83 versus the current $148.31.